Effectiveness and Safety of Anticoagulants Among Patients with Venous Thromboembolism and Common Cancers or Cancers with High Venous Thromboembolism Risk

References

• Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J. Thromb. Haemost. 5(3), 632–634 (2007).
   PubMed Web of Science ®Google Scholar
• Gussoni G, Frasson S, La Regina M, Di Micco P, Monreal M. Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. Thromb. Res. 131(1), 24–30 (2013).
   PubMed Web of Science ®Google Scholar
• Lyman GH, Culakova E, Poniewierski MS, Kuderer NM. Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer. Thromb. Res. 164(Suppl. 1), S112–S118 (2018).
   PubMedGoogle Scholar
• Key NS, Khorana AA, Kuderer NM et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update. J. Clin. Oncol. 38(5), 496–520 (2020).
   PubMed Web of Science ®Google Scholar
• Donnellan E, Khorana AA. Cancer and venous thromboembolic disease: A Review. Oncologist. 22(2), 199–207 (2017).
   PubMed Web of Science ®Google Scholar
• Khorana AA, Mackman N, Falanga A et al. Cancer-associated venous thromboembolism. Nat. Rev. Dis. Primers. 8(1), 11 (2022).
   PubMedGoogle Scholar
• Heit JA. Epidemiology of venous thromboembolism. Nat. Rev. Cardiol. 12(8), 464–474 (2015).
   PubMed Web of Science ®Google Scholar
• Roberti R, Iannone LF, Palleria C et al. Direct oral anticoagulants: from randomized clinical trials to real-world clinical practice. Front. Pharmacol. 12, 684638 (2021).
   PubMed Web of Science ®Google Scholar
• Lee AY, Levine MN, Baker RI et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med. 349(2), 146–153 (2003).
   PubMed Web of Science ®Google Scholar
• Gu Z-C, Yan Y-D, Yang S-Y et al. Direct versus conventional anticoagulants for treatment of cancer associated thrombosis: a pooled and interaction analysis between observational studies and randomized clinical trials. Ann. Transl. Med. 8(4), 95 (2020).
   PubMed Web of Science ®Google Scholar
• Douros A, Filliter C, Azoulay L, Tagalakis V. Effectiveness and safety of direct oral anticoagulants in patients with cancer associated venous thromboembolism. Thromb. Res. 202, 128–133 (2021).
   PubMed Web of Science ®Google Scholar
• McBane RD 2nd , Wysokinski WE, Le-Rademacher JG et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J. Thromb. Haemost. 18(2), 411–21 (2020).
   PubMed Web of Science ®Google Scholar
• Mulder FI, Bosch F, Young AM et al. Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. Blood 136(12), 1433–1441 (2020).
   PubMed Web of Science ®Google Scholar
• Carrier M, Abou-Nassar K, Mallick R et al. Apixaban to prevent venous thromboembolism in patients with cancer. N. Engl. J. Med. 380(8), 711–719 (2019).
   PubMed Web of Science ®Google Scholar
• Agnelli G, Becattini C, Meyer G et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N. Engl. J. Med. 382(17), 1599–607 (2020).
   PubMed Web of Science ®Google Scholar
• Riaz IB, Fuentes HE, Naqvi SAA et al. Direct oral anticoagulants compared with dalteparin for treatment of cancer-associated thrombosis: a living, interactive systematic review and network meta-analysis. Mayo Clin. Proc. 97(2), 308–324 (2022).
   PubMed Web of Science ®Google Scholar
• Mahé I, Chidiac J, Bertoletti L et al. The clinical course of venous thromboembolism may differ according to cancer site. Am. J. Med. 130(3), 337–47 (2017).
   PubMed Web of Science ®Google Scholar
• Agnelli G, Muñoz A, Franco L et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thromb. Haemost. 122(5), 796–807 (2022).
   PubMedGoogle Scholar
• Lecumberri R, Ruiz-Artacho P, Tzoran I et al. Outcome of cancer-associated venous thromboembolism is more favorable among patients with hematologic malignancies than in those with solid tumors. Thromb. Haemost. 122(9), 1594–1602 (2022).
   PubMedGoogle Scholar
• Mulder FI, van Es N, Kraaijpoel N et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study. Thromb. Res. 185, 13–19 (2020).
   PubMed Web of Science ®Google Scholar
• Rungjirajittranon T, Owattanapanich W, Chinthammitr Y, Ruchutrakool T, Suwanawiboon B. Direct oral anticoagulants versus low-molecular-weight heparin for acute treatment of venous thromboembolism in patients with gastrointestinal cancer: a systematic review and meta-analysis. Thromb. J. 20(1), 41 (2022).
   PubMed Web of Science ®Google Scholar
• Raskob GE, van Es N, Verhamme P et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N. Engl. J. Med. 378(7), 615–624 (2018).
   PubMed Web of Science ®Google Scholar
• Young AM, Marshall A, Thirlwall J et al. Comparison of an oral Factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J. Clin. Oncol. 36(20), 2017–2023 (2018).
   PubMed Web of Science ®Google Scholar
• Cohen AT, Keshishian A, Lee T et al. Effectiveness and safety of apixaban, LMWH, and warfarin among high-risk subgroups of VTE patients with active cancer. Curr. Med. Res. Opin. 37(9), 1467–1482 (2021).
   PubMed Web of Science ®Google Scholar
• Sorigue M, Cañamero E, Siguenza P, Nomdedeu M, López-Núñez JJ. Recent developments and persisting challenges in the prevention and treatment of venous thromboembolism in patients with hematological malignancies. Leuk. Lymphoma 61(6), 1277–1291 (2020).
   PubMed Web of Science ®Google Scholar
• Lyman GH, Carrier M, Ay C et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood. Adv. 5(4), 927–974 (2021).
   PubMed Web of Science ®Google Scholar
• Living Interactive Systematic Reviews . Direct oral anti-coagulants compared to dalteparin for treatment of cancer associated thrombosis: a living, interactive systematic review and network meta-analysis (2022). https://cat.network-meta-analysis.com
   Google Scholar
• Planquette B, Bertoletti L, Charles-Nelson A et al. Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial. Chest 161(3), 781–790 (2022).
   PubMed Web of Science ®Google Scholar
• National Cancer Institute Cancer Stat Facts: Common Cancer Sites (2022). https://seer.cancer.gov/statfacts/html/common.html
   Google Scholar
• Kraaijpoel N, Carrier M. How I treat cancer-associated venous thromboembolism. Blood 133(4), 291–298 (2019).
   PubMed Web of Science ®Google Scholar
• Cohen A, Noxon V, Dhamane A et al. Effectiveness and safety of anticoagulants among venous thromboembolism cancer patients with and without brain cancer. Thromb. Res. 226, 117–126 (2023).
   PubMed Web of Science ®Google Scholar
• Cornell RF, Goldhaber SZ, Engelhardt BG et al. Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents. Br. J. Haematol. 190(4), 555–561 (2020).
   PubMed Web of Science ®Google Scholar
• Farge D, Frere C, Connors JM et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet. Oncol. 23(7), e334–e347 (2022).
   PubMed Web of Science ®Google Scholar
• Thapa N, Shatzel J, Deloughery TG, Olson SR. Direct oral anticoagulants in gastrointestinal malignancies: is the convenience worth the risk? J. Gastrointest. Oncol. 10(4), 807–809 (2019).
   PubMed Web of Science ®Google Scholar
• Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. Subcommittee on Control of Anticoagulation . Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J. Thromb. Haemost. 13(11), 2119–2126 (2015).
   PubMed Web of Science ®Google Scholar